News
February 13, 2006
Experienced Scientific Researcher Joins Advaxis To Advance Development Of Cancer Vaccines
North Brunswick, NJ � February 13, 2006 -- Advaxis, Inc. (OTCBB: ADXS) today announced that Anu Wallecha, Ph.D has joined the scientific development team, and will be responsible for the advancement and development of the Lovaxin family of vaccines. Dr. Wallecha will work under the direction of Dr. Vafa Shahabi, Director of Research and Development, at the Advaxis laboratories in North Brunswick, New Jersey. Dr. Wallecha�s vast experience with the Listeria system affords Advaxis the ability to both rapidly advance existing targets as well as develop yet unannounced clinical targets. Dr. Wallecha�s expertise also expands Advaxis� ability to collaborate with potential partners.
Roni Appel, Chief Executive Officer of Advaxis, commented: "This highly skilled scientist brings to Advaxis exceptional analytic and technical skills, as well as extensive experience working with Listeria vaccine technology. Dr. Wallecha will strengthen our R & D team and help to accelerate the development of several cancer vaccines in our pipeline. This is a significant accomplishment for the company."
As a postdoctoral fellow at the University of Pennsylvania School of Medicine Department of Microbiology , Dr. Wallecha has been working alongside Dr. Yvonne Paterson, the inventor of Advaxis� vaccine technology, on an attenuated recombinant Listeria monocyogenes vaccine for HIV, as well as on certain aspects of Advaxis� Lovaxin T, its Telomerase-based cancer vaccine since 2004. Previously, Dr. Wallecha worked at the University of Pennsylvania with Dr. Marjan Van Woude on the regulation of the expression of an outer membrane protein, agn43 in Escherichia coli. Dr. Wallecha has co-authored several research papers that have appeared in the Journal of Bacteriology. She holds a Ph. D. from the Department of Biochemical Engineering and Biotechnology, Indian Institute of Technology, Delhi, India.
About Advaxis
Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania, and chairperson of Advaxis' Scientific Advisory Board. Advaxis' is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Listeria monocytogenes based system, which utilizes two immunological mechanisms (Innate and Classical Immunity) to develop safer and more effective Listeria based cancer vaccines. Advaxis is the exclusive licensee of a patented broadly enabling Listeria platform technology that can elicit effective anti-tumor responses. Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets cervical and head and neck cancers. Further Listeria vaccines in development target breast, ovarian and lung cancers. Advaxis has entered a Phase I/II clinical trial. The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forwardlooking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Company Contact:
Advaxis, Inc.
Roni Appel, 201-750-2347
Investor Relations/Public Relations Contact:
Erik Lux/Adam Holdsworth, Investor Relations
Janet Vasquez, Public Relations
212-825-3210